Peter Wirth
Chairman at SYROS PHARMACEUTICALS, INC.
Net worth: 6 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Marsha Fanucci | F | 70 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 13 years |
| Nancy Simonian | M | 63 | 12 years | |
| Gerald Quirk | M | 56 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 16 years |
| James N. Campbell | M | 76 | 11 years | |
| Thomas Wiggans | M | 72 |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 3 years |
| Selwyn Vickers | M | 64 |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 2 years |
| Wayne Frederick | M | 52 |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 3 years |
| Peter Kolchinsky | M | 47 |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 4 years |
| Richard Young | M | 70 | 13 years | |
| Ya jing Chen | M | 56 | 3 years | |
| Conley Chee | M | 54 | 3 years | |
| Jeffrey Kindler | M | 68 | 11 years | |
| Arturo Molina | M | 65 |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 1 years |
| Ying Du | M | 59 | 10 years | |
| Karen Hunady | F | - | 2 years | |
| Jeannette Potts | M | 62 | 5 years | |
| Tim Tyson | M | 71 | 2 years | |
| Andrew Oh | M | 53 | 2 years | |
| F. Edmondson | M | 58 | 4 years | |
| Michel Vounatsos | M | 62 | 1 years | |
| Scott Morrison | M | 66 | 3 years | |
| Richard Gaynor | M | 74 | 3 years | |
| Ulrich Christian Otte | M | - | 2 years | |
| Lina Zhang | F | - | - | |
| Srini Akkaraju Akkaraju | M | 56 | 7 years | |
| Kai Xian Chen | M | 78 | 6 years | |
| Raj Bhikhu Parekh | M | 63 | 9 years | |
| Joshua Smiley | M | 54 | 2 years | |
| Deborah Dunsire | M | 61 | 3 years | |
| William Lis | M | 59 | 6 years | |
| S. Gail Eckhardt | M | 66 | 4 years | |
| Wing Yu Leung | F | 53 | 10 years | |
| Sol Barer | M | 76 | 11 years | |
| John D. Diekman | M | 81 | 7 years | |
| Lonnie Moulder | M | 66 | 5 years | |
| Peter Huang | M | - | 2 years | |
| Steve Benz | M | - | 2 years | |
| Irena Webster | F | - |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | - |
| Ifeyinwa Osunkwo | M | - | 2 years | |
| Arnold Lewis Oronsky | M | 83 | 11 years | |
| Kristin Stephens | F | 51 | - | |
| Daniel Mendelson | M | 60 | 6 years | |
| Thomas Haagen | M | 58 | 2 years | |
| Sara Nayeem | M | 75 | 6 years | |
| Jonathan Wang | M | 42 | 10 years | |
| James Yan | M | 60 | 4 years | |
| Ning Xu | M | 59 | 10 years | |
| Hong Bo Lu | M | 53 | 5 years | |
| Shawn Tomasello | F | 65 | 7 years | |
| David Roth | M | 61 | 9 years | |
| Paul M. DeLuca | M | - |
University of Wisconsin
| 53 years |
| Todd Shegog | M | 59 | 5 years | |
| Mary Wadlinger | F | 64 | 10 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sanj Patel | M | 54 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 19 years |
| Henri A. Termeer | M | 78 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 28 years |
| Tao Fu | M | 52 | 5 years | |
| Felix Baker | M | 55 | 15 years | |
| Michael A. Foley | M | 62 | 9 years | |
| Marietta Wu | M | 56 | 4 years | |
| Kyle Kuvalanka | M | 56 | 2 years | |
| Christopher Viehbacher | M | 64 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
| Mark Goldberg | M | 69 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 18 years |
| Frank Lee | M | 56 | 3 years | |
| George Michael Douglas | M | - |
University of Wisconsin
| 6 years |
| Michal Silverberg | F | 48 | 3 years | |
| Thomas Beetham | M | 55 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 10 years |
| Ronald Abraham | M | - |
University of Wisconsin
| 5 years |
| Eugene W. Gerner | M | 76 |
University of Wisconsin
| 5 years |
| Jorge Conde | M | 47 | 3 years | |
| Gloria Matthews | M | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 6 years |
| Steve Alley | M | 71 |
University of Wisconsin
| 5 years |
| Alicia Secor | F | 62 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 15 years |
| Lloyd J. Dickinson | M | 76 |
University of Wisconsin
| 8 years |
| Paolo Augusto Paoletti | M | 73 | 6 years | |
| Stephen Mahoney | M | 53 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 12 years |
| Stéphane Bancel | M | 51 | 4 years | |
| A. Betz | M | 77 |
University of Wisconsin
| 8 years |
| Mike Harris | M | - |
University of Wisconsin
| 5 years |
| Rafael Amado | M | 60 | - | |
| David P. Metzger | M | - |
University of Wisconsin
| 8 years |
| Albert R. Zimmerli | M | 72 |
University of Wisconsin
| 5 years |
| Jerome R. Baier | M | - |
University of Wisconsin
| 5 years |
| Phillip Sharp | M | 79 | 10 years | |
| Robert Nelsen | M | 60 | 7 years | |
| Vicki Sato | M | 75 | 6 years | |
| Tom Stevens | M | - |
University of Wisconsin
| 6 years |
| James R. Zuhlke | M | 77 |
University of Wisconsin
| 7 years |
| Cornelius McGillicuddy | M | 83 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
| Dave D. Halford | M | 77 |
University of Wisconsin
| 7 years |
| Amir Nashat | M | 51 | 8 years | |
| James R. Behnke | M | - |
University of Wisconsin
| 4 years |
| Tom Frisbie | M | 72 |
University of Wisconsin
| 6 years |
| Daniel L. Goelzer | M | - |
University of Wisconsin
| 8 years |
| Barrett L. Browning | M | - |
University of Wisconsin
| 8 years |
| Paula Ragan | M | 54 |
Lysosomal Therapeutics, Inc.
 Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA.
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 7 years |
| Louis J. Arcudi | M | 63 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 5 years |
| Stephen S. Kolkhorst | M | - |
University of Wisconsin
| 6 years |
| Steve Hall | M | 69 | 11 years | |
| Michael Wyzga | M | 69 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 13 years |
| Terry Hefty | M | - |
University of Wisconsin
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 80 | 80.00% |
| Cayman Islands | 20 | 20.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter Wirth
- Personal Network